Sign In
Buy UTHR
$535.57
-11.49 (-2.10%)
At Close: Jul 13, 2026
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
03:30pm, Thursday, 09'th Jul 2026
UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy
06:45pm, Monday, 06'th Jul 2026
United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage pipeline. Management expects to exit 2027 with a $1 billion quarterly revenue run rate from current
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises
08:45am, Monday, 06'th Jul 2026
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
09:55am, Friday, 03'rd Jul 2026
United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
United Therapeutics Corporation Acquires Thymmune Therapeutics
06:30am, Thursday, 02'nd Jul 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately h
14 value stocks of companies primed for rapid growth through 2028
12:10pm, Wednesday, 01'st Jul 2026
Let us begin with a midyear summary of index results that might surprise you in light of the triple-digit gains for so many growth stocks in the S&P 500.
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
06:30am, Monday, 29'th Jun 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra
These 3 Stocks Lowered Their Share Counts Drastically in Q1
09:35am, Tuesday, 09'th Jun 2026
While markets often view large-scale buyback authorizations as positives in and of themselves, authorizations are just one part of the buyback equation. Unlike dividends, which companies must pay afte
Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?
12:35pm, Friday, 05'th Jun 2026
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
SDZNY or UTHR: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 04'th Jun 2026
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and United Therapeutics (UTHR). But which of these two stocks presen
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
03:41pm, Wednesday, 03'rd Jun 2026
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Jim Simons' fund bet early on Micron; Here's the fund's top stocks now
07:09am, Friday, 29'th May 2026
While the latest stock market upsurge turned Micron (NASDAQ: MU) into a household name, Jim Simons made a prodigious investment in the memory company as far back as 2013 – when it was trading at app
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
07:00am, Wednesday, 27'th May 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will prov
United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
03:10pm, Tuesday, 19'th May 2026
United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medici
